Penicillin Allergy: a Practical Approach to Assessment and Prescribing

Total Page:16

File Type:pdf, Size:1020Kb

Load more

VOLUME 42 : NUMBER 6 : DECEMBER 2019 ARTICLE Penicillin allergy: a practical approach to assessment and prescribing Misha Devchand Infectious diseases SUMMARY antimicrobial stewardship pharmacist1,2 Penicillin allergies are not always lifelong. Approximately 50% are lost over five years. Jason A Trubiano A reaction to penicillin during a childhood infection is unlikely to be a true allergy. Director1 Postdoctoral fellow 3 Only 1–2% of patients with a confirmed penicillin allergy have an allergy to cephalosporins. Research fellow4 In patients with a low risk of severe allergic reactions, cephalosporins are a relatively safe treatment option. 1 Antimicrobial Stewardship, Drug and Antibiotic Allergy Patients with a history of delayed non-severe reactions, such as mild childhood rashes that Service and Centre for occurred over 10 years ago, may be suitable for an oral rechallenge with low-dose penicillin. This Antibiotic Allergy and should be done in a supervised hospital environment. Research, Austin Health 2 Pharmacy Department, In many cases, with appropriate assessment and allergy testing, it may be possible to remove the Austin Health penicillin allergy label. 3 The National Centre for Infections in Cancer, Peter 3 10 MacCallum Cancer Centre Introduction stay, hospital readmission rates, surgical site infections,14 and admissions to intensive care units.15 4 Department of Medicine, Most patients who say they have a penicillin allergy Austin Health, University of are not allergic to penicillins. While 10% of the Similarly in general practice, penicillin allergy labels Melbourne population will report a penicillin allergy, less than 1% are associated with an increased risk of death and 16 Melbourne will be truly allergic.1,2 They have been erroneously MRSA infection or colonisation. labelled as penicillin-allergic. Impermanent allergy Keywords In the USA, penicillin allergies are the most commonly It has been demonstrated that more than 90% of beta-lactams, documented drug allergy, with up to 20% of cephalosporins, patients labelled as having a penicillin allergy would hypersensitivity hospitalised patients having a recorded penicillin be able to tolerate penicillins following appropriate 3,4 allergy. In Australian hospitals, national point assessment and allergy testing.17-19 Even penicillin prevalence data (2013–14) show that 8.9% of patients allergies confirmed by skin tests can wane over time. Aust Prescr 2019;42:192–9 5 have a penicillin allergy label on their medical record. A Half the patients who have a positive skin test for https://doi.org/10.18773/ high proportion of these labels are likely to be incorrect. 13,20 austprescr.2019.065 penicillins will lose that reactivity after five years. The patient may have had a non-immune-mediated There is therefore interest in penicillin allergy reaction such as nausea and vomiting, an exanthema ‘de-labelling’. This is the removal of the allergy label (e.g. after taking amoxicillin during an Epstein-Barr following either allergy history reconciliation or testing 6,7 virus infection) or an injection-site reaction. (oral provocation or skin testing). Impact of allergy labels What is true penicillin allergy? Patient-reported penicillin allergies alter antibiotic The classification of a patient-reported penicillin management and may result in the use of suboptimal allergy label is the first important step in appropriate or broader spectrum drugs such as fluoroquinolones, care (Table 1). Before prescribing, ask patients about 6,8-11 macrolides, glycopeptides and cephalosporins. their allergies, as not all allergies may have been Having a penicillin allergy label has been associated documented in their medical records. Conversely, with an increased risk of Clostridium difficile, some reactions labelled as allergic may be other types methicillin-resistant Staphylococcus aureus (MRSA), of adverse events. Ask about the clinical features of and vancomycin-resistant enterococci infections and suspected reactions. colonisation.3 The increased use of broad-spectrum drugs in hospitalised patients with penicillin allergies Allergic cross-reactivity also contributes to the growing global problem of The beta-lactam antibiotics include penicillins, antimicrobial resistance.6,9,12,13 Antibiotic allergy labels cephalosporins, carbapenems and monobactams. are correlated with increases in length of hospital Previously it was thought that patients with penicillin 192 Full text free online at nps.org.au/australian-prescriber © 2019 NPS MedicineWise VOLUME 42 : NUMBER 6 : DECEMBER 2019 ARTICLE Table 1 Antibiotic allergy classifications Type Mechanism Clinical examples Common antibiotic examples Antibiotic recommendation Type A adverse drug reactions – non-immune-mediated Non-severe Nausea, vomiting, diarrhoea, pruritis Beta-lactams Use all antibiotics (without rash), headache Pharmacologically predictable reactions Severe Encephalitis, renal impairment, Cefepime, aminoglycosides, Only avoid the implicated drug tendinopathy fluoroquinolones or dose Type B adverse drug reactions – immune-mediated 1 IgE-mediated Urticaria, angioedema, Penicillins, cephalosporins bronchospasm, anaphylaxis 2 Antibody (usually Haemolytic anaemia, Penicillins, cephalosporins Avoid implicated drug. Caution IgG)-mediated cell thrombocytopenia, vasculitis with drugs in the same class destruction and structurally related drugs 3 IgG or IgM and Fever, rash, arthralgia Penicillin, amoxicillin, cefaclor complement 4 T-cell mediated Maculopapular exanthema, drug Beta-lactams, glycopeptides, Avoid implicated drug, reaction with eosinophilia and sulfonamides drugs in the same class and systemic symptoms (DRESS), structurally related drugs Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalised exanthematous pustulosis Anaphylactoid reactions – non-immune-mediated Non-IgE- Direct mast-cell Flushing, itching, urticaria, Vancomycin, macrolides, Manage the reaction, mediated stimulation or angioedema fluoroquinolones either by slowing the basophil activation infusion or premedication (with antihistamines or corticosteroids) allergies had a 10% risk of cross-reactivity with patients reporting a severe-immediate cefalexin cephalosporins and carbapenems.21 However, reviews hypersensitivity, intradermal tests determined that six have reported that the risk of cross-reactivity between (40%) would not be able to tolerate ampicillin.5,28 cephalosporins, carbapenems and penicillins may be While the data regarding cross-reactivity have as low as 1%.21-24 primarily been about immediate hypersensitivities, The cross-reactivity between beta-lactam antibiotics similar patterns have been reported in non-severe 29,30 [Author: is Ref 28 may be due to the beta-lactam ring itself, an delayed penicillin allergies. There are limited published?] adjacent thiazolidine or dihydrothiazine ring, or data regarding cross-reactivity in severe delayed from the side chains (R1 in penicillins or R1 and R2 in reactions, such as Stevens-Johnson syndrome, toxic cephalosporins) – see Fig. 1. True cross-reactivity is epidermal necrolysis, drug reaction with eosinophilia largely due to the R1 side chains, with the highest risk and systemic symptoms, and acute generalised being in beta-lactams with identical side chains. exanthematous pustulosis. For these severe delayed reactions, information regarding cross-reactivity is not Cross-reactivity is particularly seen with a reliable guide for empirical prescribing. aminopenicillins (amoxicillin, ampicillin) and aminocephalosporins (cefalexin, cefaclor, cefadroxil, Assessing penicillin allergies ceprozil).24 The rate of cross-reactivity between The key to both prescribing and de-labelling for aminopenicillins and aminocephalosporins has been patients with a history of penicillin allergy is an reported to be as high as 30–40% in predominately accurate assessment. This involves an understanding European studies.23,25-27 At the antibiotic allergy of the allergy particularly the severity, timing and testing centres of Austin Health and the Peter tolerance. Therapeutic Guidelines: Antibiotic contains MacCallum Cancer Centre in Melbourne, out of 15 a guide for this assessment (Fig. 2).31 Full text free online at nps.org.au/australian-prescriber 193 VOLUME 42 : NUMBER 6 : DECEMBER 2019 ARTICLE Penicillin allergy Fig. 1 Rates of cross-reactivity between beta-lactam antibiotics Basic structures Beta-lactam structures and rates of cross-reactivity Clinically relevant cross-reactivity <2%* Beta-lactam ring Penicillins Cephalosporins Similar side chains – penicillins (R1): 0 H 0 H • penicillin VK and NH penicillin G R R C 0 1 C N S CH3 1 N S Shared side chains – CH 3 penicillins and N N R cephalosporins (R1): Penicillin structure 0 0 0 2 ‡ HO • amoxicillin , Acyl side chain ‡ Thiazolidine ampicillin , cefalexin, 0 H ring cefaclor None R1 <1% <1% Shared side chains – C N S CH3 cephalosporins (R1): CH 3 • cefalexin, cefaclor N 0 0 • cefepime, ceftriaxone, cefotaxime Beta-lactam ring HO Monobactams† Carbapenems None • ceftazidime, aztreonam 0 H R Cephalosporin structure 2 R1 No shared side chains – R1 C N R3 Acyl side chain penicillins and cephalosporins (R1): Dihydrothiazine N 0 H N 0 ring 0 0 • cefazolin R 0 S 1 C N HO S 0 OH N R 0 2 Beta-lactam ring Beta-lactam antibiotics include penicillins, cephalosporins, carbapenems and monobactams. The left panel shows basic structures of beta-lactam antibiotics. Cross-reactivity is possible through the core beta-lactam ring, adjacent thiazolidine (penicillin) or dihydrothiazine
Recommended publications
  • Mediated Peptidoglycan Cross-Linking and B-Lactam Resistance In

    Mediated Peptidoglycan Cross-Linking and B-Lactam Resistance In

    RESEARCH ARTICLE Factors essential for L,D-transpeptidase- mediated peptidoglycan cross-linking and b-lactam resistance in Escherichia coli Jean-Emmanuel Hugonnet1,2,3, Dominique Mengin-Lecreulx4, Alejandro Monton5, Tanneke den Blaauwen5, Etienne Carbonnelle1,2,3, Carole Veckerle´ 1,2,3, Yves, V. Brun6, Michael van Nieuwenhze6, Christiane Bouchier7, Kuyek Tu1,2,3, Louis B Rice8, Michel Arthur1,2,3* 1INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France; 2Sorbonne Universite´s, UPMC Universite´ Paris 06, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France; 3Universite´ Paris Descartes, Sorbonne Paris Cite´, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France; 4Institute for Integrative Biology of the Cell (I2BC), CEA, CNRS, Universite´ Paris-Sud, Universite´ Paris-Saclay, Gif-sur-Yvette, France; 5Bacterial Cell Biology and Physiology, Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, Netherlands; 6Indiana University, Indiana, United States; 7Institut Pasteur, Paris, France; 8Rhode Island Hospital, Brown University, Providence, United States Abstract The target of b-lactam antibiotics is the D,D-transpeptidase activity of penicillin- binding proteins (PBPs) for synthesis of 4fi3 cross-links in the peptidoglycan of bacterial cell walls. Unusual 3fi3 cross-links formed by L,D-transpeptidases were first detected in Escherichia coli more than four decades ago, however no phenotype has previously been associated with their synthesis. Here we show that production of the L,D-transpeptidase YcbB in combination with elevated *For correspondence: michel. synthesis of the (p)ppGpp alarmone by RelA lead to full bypass of the D,D-transpeptidase activity [email protected] of PBPs and to broad-spectrum b-lactam resistance.
  • Medical Review(S) Clinical Review

    Medical Review(S) Clinical Review

    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) December 29, 2009 Received Date(s) December 30, 2009 PDUFA Goal Date October 30, 2010 Division / Office Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products Reviewer Name(s) Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD Review Completion October 29, 2010 Date Established Name Ceftaroline fosamil for injection (Proposed) Trade Name Teflaro Therapeutic Class Cephalosporin; ß-lactams Applicant Cerexa, Inc. Forest Laboratories, Inc. Formulation(s) 400 mg/vial and 600 mg/vial Intravenous Dosing Regimen 600 mg every 12 hours by IV infusion Indication(s) Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Community-acquired Bacterial Pneumonia (CABP) Intended Population(s) Adults ≥ 18 years of age Template Version: March 6, 2009 Reference ID: 2857265 Clinical Review Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD NDA 200327: Teflaro (ceftaroline fosamil) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 9 1.1 Recommendation on Regulatory Action ........................................................... 10 1.2 Risk Benefit Assessment.................................................................................. 10 1.3 Recommendations for Postmarketing Risk Evaluation and Mitigation Strategies ........................................................................................................................
  • Pharmacodynamic Evaluation of Suppression of in Vitro Resistance In

    Pharmacodynamic Evaluation of Suppression of in Vitro Resistance In

    www.nature.com/scientificreports OPEN Pharmacodynamic evaluation of suppression of in vitro resistance in Acinetobacter baumannii strains using polymyxin B‑based combination therapy Nayara Helisandra Fedrigo1, Danielle Rosani Shinohara1, Josmar Mazucheli2, Sheila Alexandra Belini Nishiyama1, Floristher Elaine Carrara‑Marroni3, Frederico Severino Martins4, Peijuan Zhu5, Mingming Yu6, Sherwin Kenneth B. Sy2 & Maria Cristina Bronharo Tognim1* The emergence of polymyxin resistance in Gram‑negative bacteria infections has motivated the use of combination therapy. This study determined the mutant selection window (MSW) of polymyxin B alone and in combination with meropenem and fosfomycin against A. baumannii strains belonging to clonal lineages I and III. To evaluate the inhibition of in vitro drug resistance, we investigate the MSW‑derived pharmacodynamic indices associated with resistance to polymyxin B administrated regimens as monotherapy and combination therapy, such as the percentage of each dosage interval that free plasma concentration was within the MSW (%TMSW) and the percentage of each dosage interval that free plasma concentration exceeded the mutant prevention concentration (%T>MPC). The MSW of polymyxin B varied between 1 and 16 µg/mL for polymyxin B‑susceptible strains. The triple combination of polymyxin B with meropenem and fosfomycin inhibited the polymyxin B‑resistant subpopulation in meropenem‑resistant isolates and polymyxin B plus meropenem as a double combination sufciently inhibited meropenem‑intermediate, and susceptible strains. T>MPC 90% was reached for polymyxin B in these combinations, while %TMSW was 0 against all strains. TMSW for meropenem and fosfomycin were also reduced. Efective antimicrobial combinations signifcantly reduced MSW. The MSW‑derived pharmacodynamic indices can be used for the selection of efective combination regimen to combat the polymyxin B‑resistant strain.
  • Efficacy of Amoxicillin and Amoxicillin/Clavulanic Acid in the Prevention of Infection and Dry Socket After Third Molar Extraction

    Efficacy of Amoxicillin and Amoxicillin/Clavulanic Acid in the Prevention of Infection and Dry Socket After Third Molar Extraction

    Med Oral Patol Oral Cir Bucal. 2016 Jul 1;21 (4):e494-504. Amoxicillin in the prevention of infectious complications after tooth extraction Journal section: Oral Surgery doi:10.4317/medoral.21139 Publication Types: Review http://dx.doi.org/doi:10.4317/medoral.21139 Efficacy of amoxicillin and amoxicillin/clavulanic acid in the prevention of infection and dry socket after third molar extraction. A systematic review and meta-analysis María-Iciar Arteagoitia 1, Luis Barbier 2, Joseba Santamaría 3, Gorka Santamaría 4, Eva Ramos 5 1 MD, DDS, PhD, Associate Professor, Stomatology I Department, University of the Basque Country (UPV/EHU), BioCruces Health Research Institute, Spain; Consolidated research group (UPV/EHU IT821-13) 2 MD PhD, Chair Professor, Maxillofacial Surgery Department, BioCruces Health Research Institute, Cruces University Hos- pital, University of the Basque Country (UPV/EHU), Spain; Consolidated research group (UPV/EHU IT821-13) 3 MD, DDS, PhD, Professor and Chair, Maxillofacial Surgery Department, Bio Cruces Health Research Institute, Cruces University Hospital, University of the Basque Country (UPV/EHU), Bizkaia, Spain; Consolidated research group (UPV/EHU IT821-13) 4 DDS, PhD, Associate Professor, Stomatology I Department, University of the Basque Country (UPV/EHU), BioCruces Health Research Institute, Spain; Consolidated research group (UPV/EHU IT821-13) 5 PhD, Degree in Farmacy, BioCruces Health Research Institute, Cruces University Hospital. Spain Correspondence: Servicio Cirugía Maxilofacial Hospital Universitario de Cruces Plaza de Cruces s/n Arteagoitia MI, Barbier L, Santamaría J, Santamaría G, Ramos E. Ef- Barakaldo, Bizkaia, Spain ficacy of amoxicillin and amoxicillin/clavulanic acid in the prevention [email protected] of infection and dry socket after third molar extraction.
  • Cefalexin in the WHO Essential Medicines List for Children Reject

    Cefalexin in the WHO Essential Medicines List for Children Reject

    Reviewer No. 1: checklist for application of: Cefalexin In the WHO Essential Medicines List for Children (1) Have all important studies that you are aware of been included? Yes No 9 (2) Is there adequate evidence of efficacy for the proposed use? Yes 9 No (3) Is there evidence of efficacy in diverse settings and/or populations? Yes 9 No (4) Are there adverse effects of concern? Yes 9 No (5) Are there special requirements or training needed for safe/effective use? Yes No 9 (6) Is this product needed to meet the majority health needs of the population? Yes No 9 (7) Is the proposed dosage form registered by a stringent regulatory authority? Yes 9 No (8) What action do you propose for the Committee to take? Reject the application for inclusion of the following presentations of cefalexin: • Tablets/ capsules 250mg • Oral suspensions 125mg/5ml and 125mg/ml (9) Additional comment, if any. In order to identify any additional literature, the following broad and sensitive search was conducted using the PubMed Clinical Query application: (cephalexin OR cefalexin AND - 1 - pediatr*) AND ((clinical[Title/Abstract] AND trial[Title/Abstract]) OR clinical trials[MeSH Terms] OR clinical trial[Publication Type] OR random*[Title/Abstract] OR random allocation[MeSH Terms] OR therapeutic use[MeSH Subheading]) Only one small additional study was identified, which looked at the provision of prophylactic antibiotics in patients presenting to an urban children's hospital with trauma to the distal fingertip, requiring repair.1 In a prospective randomised control trial, 146 patients were enrolled, of which 69 were randomised to the no-antibiotic group, and 66 were randomised to the antibiotic (cefalexin) group.
  • General Items

    General Items

    Essential Medicines List (EML) 2019 Application for the inclusion of imipenem/cilastatin, meropenem and amoxicillin/clavulanic acid in the WHO Model List of Essential Medicines, as reserve second-line drugs for the treatment of multidrug-resistant tuberculosis (complementary lists of anti-tuberculosis drugs for use in adults and children) General items 1. Summary statement of the proposal for inclusion, change or deletion This application concerns the updating of the forthcoming WHO Model List of Essential Medicines (EML) and WHO Model List of Essential Medicines for Children (EMLc) to include the following medicines: 1) Imipenem/cilastatin (Imp-Cln) to the main list but NOT the children’s list (it is already mentioned on both lists as an option in section 6.2.1 Beta Lactam medicines) 2) Meropenem (Mpm) to both the main and the children’s lists (it is already on the list as treatment for meningitis in section 6.2.1 Beta Lactam medicines) 3) Clavulanic acid to both the main and the children’s lists (it is already listed as amoxicillin/clavulanic acid (Amx-Clv), the only commercially available preparation of clavulanic acid, in section 6.2.1 Beta Lactam medicines) This application makes reference to amendments recommended in particular to section 6.2.4 Antituberculosis medicines in the latest editions of both the main EML (20th list) and the EMLc (6th list) released in 2017 (1),(2). On the basis of the most recent Guideline Development Group advising WHO on the revision of its guidelines for the treatment of multidrug- or rifampicin-resistant (MDR/RR-TB)(3), the applicant considers that the three agents concerned be viewed as essential medicines for these forms of TB in countries.
  • Simultaneous Determination of Amoxicillin and Clavulanic Acid in Pharmaceutical Preparations by Capillary Zone Electrophoresis

    Simultaneous Determination of Amoxicillin and Clavulanic Acid in Pharmaceutical Preparations by Capillary Zone Electrophoresis

    Brazilian Journal of Pharmaceutical Sciences vol. 52, n. 2, apr./jun., 2016 Article http://dx.doi.org/10.1590/S1984-82502016000200006 Simultaneous determination of amoxicillin and clavulanic acid in pharmaceutical preparations by capillary zone electrophoresis Gabriel Hancu1,*, Anamaria Neacşu1, Lajos Attila Papp1, Adriana Ciurba2 1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Medicine and Pharmacy, TîrguMureş, Romania, 2Department of PharmaceuticalTechnology, Faculty of Pharmacy, University of Medicine and Pharmacy, Tîrgu Mureş, Romania Clavulanic acid enhances the antibacterial spectrum of amoxicillin by rendering most β-lactamase producing isolates susceptible to the drug. A fast, simple and efficient capillary electrophoresis method was developed for the simultaneous determination of amoxicillin and clavulanic acid from complex mixtures. Using a 25 mM sodium tetraborate as background electrolyte at a pH of 9.30, + 25 kV applied voltage, 25 °C system temperature, UV determination at 230 nm; we succeeded in simultaneous separation of amoxicillin and clavulanic acid in approximately 2 minutes. The analytical performance of the method was evaluated in terms of reproducibility, precision, accuracy, and linearity. The optimized analytical method was applied for the determination of the two analytes from combined commercial pharmaceutical preparations. This CE method is fast, inexpensive, efficient, and environmentally friendly when compared with the more frequently used high performance liquid chromatography methods described in the literature. Uniterms: Amoxicillin/determination. Clavulanic acid/determination. Capillary electrophoresis/ quantitative analysis. Antibacterials/quantitative analysis. O ácido clavulânico acentua o espectro antibacteriano de amoxicilina, tornando a maioria dos isolados produtores de β-lactamase sensíveis ao fármaco. Desenvolveu-se um método rápido, simples e eficiente de electroforese capilar (EC) para a determinação simultânea de amoxicilina e de ácido clavulânico a partir de misturas complexas.
  • Severe Sepsis and Septic Shock Antibiotic Guide

    Severe Sepsis and Septic Shock Antibiotic Guide

    Stanford Health Issue Date: 05/2017 Stanford Antimicrobial Safety and Sustainability Program Severe Sepsis and Septic Shock Antibiotic Guide Table 1: Antibiotic selection options for healthcare associated and/or immunocompromised patients • Healthcare associated: intravenous therapy, wound care, or intravenous chemotherapy within the prior 30 days, residence in a nursing home or other long-term care facility, hospitalization in an acute care hospital for two or more days within the prior 90 days, attendance at a hospital or hemodialysis clinic within the prior 30 days • Immunocompromised: Receiving chemotherapy, known systemic cancer not in remission, ANC <500, severe cell-mediated immune deficiency Table 2: Antibiotic selection options for community acquired, immunocompetent patients Table 3: Antibiotic selection options for patients with simple sepsis, community acquired, immunocompetent patients requiring hospitalization. Risk Factors for Select Organisms P. aeruginosa MRSA Invasive Candidiasis VRE (and other resistant GNR) Community acquired: • Known colonization with MDROs • Central venous catheter • Liver transplant • Prior IV antibiotics within 90 day • Recent MRSA infection • Broad-spectrum antibiotics • Known colonization • Known colonization with MDROs • Known MRSA colonization • + 1 of the following risk factors: • Prolonged broad antibacterial • Skin & Skin Structure and/or IV access site: ♦ Parenteral nutrition therapy Hospital acquired: ♦ Purulence ♦ Dialysis • Prolonged profound • Prior IV antibiotics within 90 days ♦ Abscess
  • Medicines to Treat Bacterial Infections

    Medicines to Treat Bacterial Infections

    Government of Western Australia North Metropolitan Health Service Women and Newborn Health Service Medicines to treat bacterial infections This brochure contains some information on Important: Antibiotic resistance can the medicines you may have been prescribed affect us all. to treat a bacterial infection either in hospital or on discharge. Please talk to your doctor or Help limit the development of antibiotic pharmacist if you would like more information resistance by using antibiotics correctly. on a specific antibiotic. Make sure you: Take antibiotics exactly as prescribed. What is an antibiotic? • Antibiotics are medicines used to treat • Follow instructions on how many times a infections caused by bacteria. They are not day and for how long to take them. effective against viral infections such as the • Do not stop treatment early, even if you common cold and the ‘flu’. feel better. Medicine Other information Amoxicillin May be taken with or without food. Amoxicillin/ Take with the first bite of a meal. clavulanic acid Cefalexin May be taken with or without food. Take on an empty stomach with a glass of water, 1 hour before or 2 hours after food. Ciprofloxacin Do not take dairy products, antacids, iron, zinc or calcium within 2 hours of the dose. Clindamycin Take with a full glass of water. May be taken with or without food. Take with food or milk. Remain upright for an hour after dose to prevent damage to the Doxycycline lining of your throat. Do not take dairy products, antacids, iron, zinc or calcium within 2 hours of the dose. Take on an empty stomach, 1 hour before or 2 hours after food.
  • Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020

    Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020

    First independent framework for assessing pharmaceutical company action Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020 ACKNOWLEDGEMENTS The Access to Medicine Foundation would like to thank the following people and organisations for their contributions to this report.1 FUNDERS The Antimicrobial Resistance Benchmark research programme is made possible with financial support from UK AID and the Dutch Ministry of Health, Welfare and Sport. Expert Review Committee Research Team Reviewers Hans Hogerzeil - Chair Gabrielle Breugelmans Christine Årdal Gregory Frank Fatema Rafiqi Karen Gallant Nina Grundmann Adrián Alonso Ruiz Hans Hogerzeil Magdalena Kettis Ruth Baron Hitesh Hurkchand Joakim Larsson Dulce Calçada Joakim Larsson Marc Mendelson Moska Hellamand Marc Mendelson Margareth Ndomondo-Sigonda Kevin Outterson Katarina Nedog Sarah Paulin (Observer) Editorial Team Andrew Singer Anna Massey Deirdre Cogan ACCESS TO MEDICINE FOUNDATION Rachel Jones The Access to Medicine Foundation is an independent Emma Ross non-profit organisation based in the Netherlands. It aims to advance access to medicine in low- and middle-income Additional contributors countries by stimulating and guiding the pharmaceutical Thomas Collin-Lefebvre industry to play a greater role in improving access to Alex Kong medicine. Nestor Papanikolaou Address Contact Naritaweg 227-A For more information about this publication, please contact 1043 CB, Amsterdam Jayasree K. Iyer, Executive Director The Netherlands [email protected] +31 (0) 20 215 35 35 www.amrbenchmark.org 1 This acknowledgement is not intended to imply that the individuals and institutions referred to above endorse About the cover: Young woman from the Antimicrobial Resistance Benchmark methodology, Brazil, where 40%-60% of infections are analyses or results.
  • Antibiotic Use Guidelines for Companion Animal Practice (2Nd Edition) Iii

    Antibiotic Use Guidelines for Companion Animal Practice (2Nd Edition) Iii

    ii Antibiotic Use Guidelines for Companion Animal Practice (2nd edition) iii Antibiotic Use Guidelines for Companion Animal Practice, 2nd edition Publisher: Companion Animal Group, Danish Veterinary Association, Peter Bangs Vej 30, 2000 Frederiksberg Authors of the guidelines: Lisbeth Rem Jessen (University of Copenhagen) Peter Damborg (University of Copenhagen) Anette Spohr (Evidensia Faxe Animal Hospital) Sandra Goericke-Pesch (University of Veterinary Medicine, Hannover) Rebecca Langhorn (University of Copenhagen) Geoffrey Houser (University of Copenhagen) Jakob Willesen (University of Copenhagen) Mette Schjærff (University of Copenhagen) Thomas Eriksen (University of Copenhagen) Tina Møller Sørensen (University of Copenhagen) Vibeke Frøkjær Jensen (DTU-VET) Flemming Obling (Greve) Luca Guardabassi (University of Copenhagen) Reproduction of extracts from these guidelines is only permitted in accordance with the agreement between the Ministry of Education and Copy-Dan. Danish copyright law restricts all other use without written permission of the publisher. Exception is granted for short excerpts for review purposes. iv Foreword The first edition of the Antibiotic Use Guidelines for Companion Animal Practice was published in autumn of 2012. The aim of the guidelines was to prevent increased antibiotic resistance. A questionnaire circulated to Danish veterinarians in 2015 (Jessen et al., DVT 10, 2016) indicated that the guidelines were well received, and particularly that active users had followed the recommendations. Despite a positive reception and the results of this survey, the actual quantity of antibiotics used is probably a better indicator of the effect of the first guidelines. Chapter two of these updated guidelines therefore details the pattern of developments in antibiotic use, as reported in DANMAP 2016 (www.danmap.org).
  • Zinforo, INN Ceftaroline Fosamil

    Zinforo, INN Ceftaroline Fosamil

    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Zinforo 600 mg powder for concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains ceftaroline fosamil acetic acid solvate monohydrate equivalent to 600 mg ceftaroline fosamil. After reconstitution, 1 ml of the solution contains 30 mg of ceftaroline fosamil. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for concentrate for solution for infusion. A pale yellowish-white to light yellow powder. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Zinforo is indicated in adults for the treatment of the following infections (see sections 4.4 and 5.1): • Complicated skin and soft tissue infections (cSSTI) • Community-acquired pneumonia (CAP) Consideration should be given to official guidance on the appropriate use of antibacterial agents. 4.2 Posology and method of administration Posology For the treatment of cSSTI and CAP, the recommended dose is 600 mg administered every 12 hours by intravenous infusion over 60 minutes in patients aged 18 years or older. The recommended treatment duration for cSSTI is 5 to 14 days and the recommended duration of treatment for CAP is 5 to 7 days. Special populations Elderly patients (≥ 65 years) No dosage adjustment is required for the elderly with creatinine clearance values > 50 ml/min (see section 5.2). Renal impairment The dose should be adjusted when creatinine clearance (CrCL) is ≤ 50 ml/min, as shown below (see sections 4.4 and 5.2). Creatinine clearance Dosage regimen Frequency (ml/min) > 30 to ≤ 50 400 mg intravenously (over 60 minutes) every 12 hours 2 There is insufficient data to make specific dosage adjustment recommendations for patients with severe renal impairment (CrCL ≤ 30 ml/min) and end-stage renal disease (ESRD), including patients undergoing haemodialysis (see section 4.4).